Program Highlights

The scientific program of ICLE 2023 will present the latest cutting-edge science in the field of lymphocyte engineering and will furthermore discuss how the new research translates for clinical implications.

To get better understanding of what will be the focus this September in Munich browse the topic highlights below.

UPDATE ON THE APPROVED THERAPIES

First look at post marketing real world data on the approved CAR-T cell therapies.

CURRENTLY ONGOING CLINICAL TRIALS

Discover clinical data from company, as well as investigator initiated trials.

NOVEL CLINICAL APPROACHES AND COMBINATION THERAPIES

Potential synergy b/n engineered lymphocytes & other treatment modalities will be demonstrated.

SUPERPOWERED LYMPHOCYTES

Learn more about engineering of lymphocytes for the co-expression of varied immune effectors in addition to the transgenic receptor.

NON-VIRAL
CAR/TCR ENGINEERING

Recent advancement in non viral lymphocyte engineering by means of electroporation or nanocarriers encapsulating mRNA or DNA.

UNIVERSAL DONOR CELLS &
ADVANCED TCR ENGINEERING

A deeper look at
allogeneic therapies,
including those applying
genome editing technologies.

BEYOND
ALPHA-BETA T CELLS

Discuss the engineering of alternative leukocytes including Gamma-Delta T cells, iNKT cells, NK cells, B cells and macrophages.

IN VIVO
T CELL ENGINEERING

Advancement in the scalable engineering of lymphocytes in vivo, reducing costs, timelines and pre conditioning requirements.

TARGETING
NON-MALIGNANT DISEASES

Targeting of non-malignant diseases, including infectious diseases, auto-immune diseases, cardiovascular diseases, genetic disorders and more.

EXPLORE THE FULL SCIENTIFIC PROGRAM